Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company focused on developing regenerative therapies across immunotherapy, endocrinology, urology, neurology, and orthopedics. Its subsidiary, Creative Medical Technologies, Inc. (CMT), initially focused on treating erectile dysfunction (ED) using U.S. Patent No. 8,372,797 and related intellectual property acquired in February 2016. The company has since broadened its intellectual property development and acquisition to include therapeutic treatments using "re-programmed" stem cells for neurologic disorders, lower back pain, Type-1 diabetes, and heart, liver, kidney, and other diseases. These efforts are conducted through its ImmCelz, Inc., StemSpine, Inc., and AlloCelz LLC subsidiaries. However, ImmCelz Inc. and AlloCelz LLC have not yet started commercial activities. In 2020, through ImmCelz Inc., the company began developing treatments under its ImmCelz™ platform (CELZ-100). This platform involves extracting a patient's own immune cells, "reprogramming/supercharging" them outside the body with optimized cell-free factors, and then re-injecting them into the same patient. The company believes this process gives the immune cells regenerative properties, enabling them to treat multiple conditions. This capability has been validated through independent third-party studies on selected human donor patient cells. Unlike other stem cell approaches, these immune cells are smaller and are believed to penetrate damaged tissues more effectively to induce regeneration. In June 2022, the company partnered with Greenstone Biosciences Inc. for the development of a human induced pluripotent stem cell (iPSC) pipeline for the ImmCelz™ platform, named iPScelz™. In May 2023, Greenstone successfully developed a human induced pluripotent stem cell (iPSC).